China’s pharmaceutical industry, whose revenue is projected to rise by 50 per cent between 2024 and 2030, has emerged as a new growth engine for the national economy as leading players ramp up investment in research and production. The country’s drug and medical device businesses were forecast to top US$2.1 trillion in revenue by 2030 and US$3.2 trillion annually by 2050, according to estimates by UBS. In 2024, the sector generated about US$1.4 trillion in sales. “An ageing population offers the...

This year is likely to be a watershed one for the global drive by Chinese electric vehicle (EV) makers, as more Western countries open up their markets to high-performance made-in-China models. Despite low expectations for a hefty jump in overseas sales, EV assemblers like BYD and Geely are expected to get off to a strong start in some of their untapped markets, honing their image as world leaders in terms of production and technology before establishing a long-term foothold, according to...

A requirement to set minimum prices for their cars in the European Union will reduce sales there for Chinese electric vehicle (EV) makers, but higher profit margins will eventually improve their bottom lines and brand reputations, according to analysts and industry officials. Assemblers of Chinese pure-electric cars from BYD to Leapmotor will avoid a brutal discount war after European authorities accepted price undertakings to replace punitive anti-subsidy tariffs of up to 35.3 per cent. Minimum...